A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer

Cancer Treatment Reviews

Volumn 39, Issue 7, 2013, Pages 720-727

  Larsen, Pia Bükmann ^a   Kümler, Iben ^a   Nielsen, Dorte Lisbet ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Brain metastases; Lapatinib; Metastatic breast cancer; Trastuzumab

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; HUMAN; OVERALL SURVIVAL; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW;

AMERICAN SOCIETY OF CLINICAL ONCOLOGY; ASCO; BBB; BLOOD BRAIN BARRIER; BM; BRAIN METASTASES; CENTRAL NERVOUS SYSTEM; CNS; COMPLETE RESPONSE; CR; EASTERN COOPERATIVE ONCOLOGY GROUP; ECOG; FDA; FOOD AND DRUG ADMINISTRATION; HER; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR; LAPATINIB; MBC; METASTATIC BREAST CANCER; OS; OVERALL SURVIVAL; PARTIAL RESPONSE; PERFORMANCE STATUS; PFS; PR; PROGRESSION FREE SURVIVAL; PS; SD; STABLE DISEASE; TIME TO PROGRESSION; TRASTUZUMAB; TTP; WBRT; WHOLE BRAIN RADIATION THERAPY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84881541385     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.01.006     Document Type: Review

References (80)

1. Preusser M., Capper D., Ilhan-Mutlu A., et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012, 123(2):205-222.
2. Nussbaum E.S., Djalilian H.R., Cho K.H., Hall W.A. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996, 78(8):1781-1788.
3. Zimm S., Wampler G.L., Stablein D., Hazra T., Young H.F. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 1981, 48(2):384-394.
4. Patchell R.A. The management of brain metastases. Cancer Treat Rev 2003, 29(6):533-540.
5. Kirsch D.G., Loeffler J.S. Brain metastases in patients with breast cancer: new horizons. Clin Breast Cancer 2005, 6(2):115-124.
6. Tsukada Y., Fouad A., Pickren J.W., Lane W.W. Central nervous system metastasis from breast carcinoma Autopsy study. Cancer 1983, 52(12):2349-2354.
7. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., Vigneau F.D., Lai P., Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973-2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004, 22(14):2865-2872.
8. Weil R.J., Palmieri D.C., Bronder J.L., Stark A.M., Steeg P.S. Breast cancer metastasis to the central nervous system. Am J Pathol 2005, 167(4):913-920.
9. Pestalozzi B.C., Zahrieh D., Price K.N., et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006, 17(6):935-944.
10. Gaspar L., Scott C., Rotman M., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37(4):745-751.
11. Slimane K., Andre F., Delaloge S., et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004, 15(11):1640-1644.
12. Neciosup S.P., Gomez H.L., Cruz W.R., et al. Risk factors for central nervous system (CNS) metastases in patients with stage I-III breast cancer 2010.
13. Gabos Z., Sinha R., Hanson J., et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006, 24(36):5658-5663.
14. Duchnowska R., Biernat W., Szostakiewicz B., et al. Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist 2012, 17(1):26-35.
15. Musolino A., Ciccolallo L., Panebianco M., et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 2011, 117(9):1837-1846.
16. Dawood S., Broglio K., Esteva F.J., et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008, 19(7):1242-1248.
17. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131(1):18-43.
18. Kallioniemi O.P., Holli K., Visakorpi T., Koivula T., Helin H.H., Isola J.J. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991, 49(5):650-655.
19. Miller K.D., Weathers T., Haney L.G., et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003, 14(7):1072-1077.
20. Bendell J.C., Domchek S.M., Burstein H.J., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97(12):2972-2977.
21. Brufsky A.M., Mayer M., Rugo H.S., et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011, 17(14):4834-4843.
22. Clayton A.J., Danson S., Jolly S., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004, 91(4):639-643.
23. Montagna E., Cancello G., D'Agostino D., et al. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. Cancer Chemother Pharmacol 2009, 63(2):275-280.
24. Mehta A.I., Brufsky A.M., Sampson J.H. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev 2012.
25. DiStefano A., Yong Yap Y., Hortobagyi G.N., Blumenschein G.R. The natural history of breast cancer patients with brain metastases. Cancer 1979, 44(5):1913-1918.
26. Patanaphan V., Salazar O.M., Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J 1988, 81(9):1109-1112.
27. Engel J., Eckel R., Aydemir U., et al. Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 2003, 55(5):1186-1195.
28. Bravo Marques J.M. Treatment of brain metastases in patients with HER2+ breast cancer. Adv Therapy 2009, Suppl. 1(Jul 26):18-26.
29. Yin W., Jiang Y., Shen Z., Shao Z, Lu J. Trastuzumab in the adjuvant traetment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One 2011, 6(6):e21030.
30. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
31. Nielsen D.L., Andersson M., Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009, 35(2):121-136.
32. Cameron D., Casey M., Oliva C., Newstat B., Imwalle B., Geyer C.E. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010, 15(9):924-934.
33. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26):2733-2743.
34. Johnston S., Pippen J., Pivot X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27(33):5538-5546.
35. Bernard-Marty C., Lebrun F., Awada A., Piccart M.J. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs 2006, 66(12):1577-1591.
36. Bartsch R., Rottenfusser A., Wenzel C., et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007, 85(3):311-317.
37. Church D.N., Modgil R., Guglani S., et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol 2008, 31(3):250-254.
38. Le Scodan R., Jouanneau L., Massard C., et al. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer 2011, 11:395.
39. Metro G., Sperduti I., Russillo M., Milella M., Cognetti F., Fabi A. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. Oncologist 2007, 12(12):1467-1469. Author reply 69-71.
40. Nam BH K.S., Han H.S., et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res Treat 2007, 10(1).
41. Park I.H., Ro J., Lee K.S., Nam B.H., Kwon Y., Shin K.H. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009, 20(1):56-62.
42. Park Y.H., Park M.J., Ji S.H., et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 2009, 100(6):894-900.
43. Witzel I., Kantelhardt E.J., Milde-Langosch K., et al. Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer. Onkologie 2011, 34(6):304-308.
44. Eichler A.F., Kuter I., Ryan P., Schapira L., Younger J., Henson J.W. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008, 112(11):2359-2367.
45. Wolstenholme V., Hawkins M., Ashley S., Tait D., Ross G. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast 2008, 17(6):661-665.
46. Chargari C., Idrissi H.R., Pierga J.Y., et al. Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients. Int J Radiat Oncol Biol Phys 2011, 81(3):631-636.
47. Dawood S., Gonzalez-Angulo A.M., Albarracin C., et al. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer 2010, 116(13):3084-3092.
48. Gori S., Montemurro F., Spazzapan S., et al. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol 2012, 23(6):1436-1441.
49. Niwinska A., Murawska M., Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 2010, 21(5):942-948.
50. Ono M., Ando M., Yunokawa M., et al. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol 2009, 14(1):48-52.
51. Metro G., Foglietta J., Russillo M., et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011, 22(3):625-630.
52. Lin N.U., Carey L.A., Liu M.C., et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008, 26(12):1993-1999.
53. Lin N.U., Dieras V., Paul D., et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009, 15(4):1452-1459.
54. Lin N.U., Eierman W., Greil R., et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 2011, 105(3):613-620.
55. Sutherland S., Ashley S., Miles D., et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases-the UK experience. Br J Cancer 2010, 102(6):995-1002.
56. Bachelot T, Romieu G, Campone M, et al. Results of the LANDSCAPE trial. Presented at ESMO 2012; Abstract 121IN.
57. Bartsch R., Berghoff A., Pluschnig U., et al. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer 2012, 106(1):25-31.
58. Kaplan M.A., Isikdogan A., Koca D., et al. Lapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology Study. J Clin Oncol 2012, (Suppl. 30).
59. Yap Y.S., Cornelio G.H., Devi B.C., et al. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer 2012.
60. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17(9):2639-2648.
61. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353(16):1659-1672.
62. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
63. Cardoso F., Costa A., Norton L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21(3):242-252.
64. Taskar K.S., Rudraraju V., Mittapalli R.K., et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res 2012, 29(3):770-781.
65. Polli J.W., Humphreys J.E., Harmon K.A., et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino }methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008, 36(4):695-701.
66. Fabi A., Vidiri A., Ferretti G., et al. Dramatic regression of multiple brain metastases from breast cancer with Capecitabine: another arrow at the bow?. Cancer Invest 2006, 24(4):466-468.
67. Hikino H., Yamada T., Johbara K., Obayashi N., Ozaki N. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast 2006, 15(1):97-99.
68. Siegelmann-Danieli N., Stein M., Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 2003, 5(11):833-834.
69. Ekenel M., Hormigo A.M., Peak S., Deangelis L.M., Abrey L.E. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 2007, 85(2):223-227.
70. Rivera E., Meyers C., Groves M., et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006, 107(6):1348-1354.
71. Bose P., Ozer H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Invest Drugs 2009, 18(11):1735-1751.
72. Burstein H.J., Sun Y., Dirix L.Y., et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010, 28(8):1301-1307.
73. Zhao X.Q., Xie J.D., Chen X.G., et al. Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance In Vitro, In Vivo, and Ex Vivo. Mol Pharmacol 2012, 82(1):47-58.
74. Perez E.A., Spano J.P. Current and emerging targeted therapies for metastatic breast cancer. Cancer 2012, 118(12):3014-3025.
75. Joensuu H K.M. LUX-breast 3: randomized phase II study of afatinib alone or with vinorelbine versus investigators choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab or lapatinib-based therapy. J Clin Oncol 2012, (Suppl. 30, 2012).
76. Baselga J., Smith B.L., Rafferty E.A., Bombonati A. Case records of the Massachusetts General Hospital. Case 16-2012. A 32-year-old woman with HER2-positive breast cancer. N Engl J Med 2012, 366(21):2018-2026.
77. Colozza M., Minenza E., Gori S., et al. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol 2009, 63(6):1157-1159.
78. Ferrario C., Davidson A., Bouganim N., Aloyz R., Panasci L.C. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol 2009, 20(4):792-795.
79. Martens J., Venuturumilli P., Corbets L., Bestul D. Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases. Acta Oncol 2012.
80. Stemmler H.J., Mengele K., Schmitt M., et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs 2008, 19(8):832-836.